| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥367.9B | ¥293.0B | +25.5% |
| Operating Income | ¥21.5B | ¥23.3B | -7.6% |
| Ordinary Income | ¥22.0B | ¥40.8B | -46.0% |
| Net Income | ¥9.8B | ¥27.7B | -64.8% |
| ROE | 6.6% | 13.7% | - |
FY2025 consolidated results: Revenue 367.9B yen (YoY +25.5%), Operating Income 21.5B yen (-7.6%), Ordinary Income 22.0B yen (-46.0%), Net Income 9.8B yen (-64.8%). The company demonstrated strong top-line momentum with revenue growth accelerating to over 25%, driven by expansion in both Recruitment Platform and Medical Platform segments as well as M&A contributions. However, profitability deteriorated significantly across all profit levels. Operating income declined 7.6% despite revenue growth, reflecting substantial SG&A expansion that outpaced revenue gains. The gap between ordinary and net income widened dramatically, with net income falling 64.8% due to an exceptionally high effective tax rate of 59.0% (income tax expense 14.0B yen on pre-tax profit 23.8B yen). Cash position decreased sharply from 189.96B yen to 85.75B yen (-54.9%), driven by M&A investments (66.2B yen in subsidiary acquisitions) and substantial share buybacks (53.3B yen). Despite the profit decline, operating cash flow remained robust at 34.9B yen (+42.5% YoY), demonstrating strong cash generation capability and representing 3.58x net income. The company continues to execute an aggressive growth strategy through acquisitions, with goodwill increasing 63.3% to 128.6B yen and intangible assets rising 36.5% to 232.5B yen, creating elevated impairment risk exposure. Full-year guidance projects revenue of 464.0B yen (+26.1% YoY) and operating income of 29.5B yen (+37.2%), indicating expected profit recovery in the remaining periods.
Revenue growth of 25.5% to 367.9B yen was broad-based across segments. Recruitment Platform business generated 263.2B yen (+24.7% YoY), representing 71.5% of total revenue and serving as the core revenue driver. Medical Platform revenue reached 93.8B yen (+27.3% YoY), demonstrating accelerated growth momentum. New Development Services contributed 10.9B yen (+78.4% YoY), reflecting early-stage expansion. The revenue expansion was supported by both organic growth in existing platforms and consolidation effects from acquisitions including ASFON TRUST NETWORK and Axis Route Holdings during the current period, as well as prior-period acquisitions of Guppies and Offshore. Gross profit increased to 231.9B yen with gross margin maintained at 63.0%, indicating pricing power and operational efficiency at the direct cost level.
However, profit deterioration was driven by disproportionate SG&A expansion. SG&A expenses surged to 210.4B yen, representing 57.2% of revenue compared to an estimated lower ratio in the prior period. Key cost drivers included goodwill amortization of 13.6B yen (up from 7.7B yen prior year, +76.6%) resulting from expanded M&A activity, and likely increases in personnel costs and system development expenses to support business scaling. The SG&A ratio rising faster than revenue growth indicates negative operating leverage, where incremental revenue is not translating into proportional profit gains. This structural cost pressure compressed operating margin from 7.9% to 5.8% (-2.1pt deterioration).
The gap between operating and ordinary income narrowed to 0.5B yen (ordinary exceeding operating by 2.3%), with non-operating income of 4.6B yen offset by non-operating expenses of 4.1B yen including interest expense of 1.7B yen on debt of 123.0B yen. The ordinary income decline of 46.0% reflects both the operating profit decrease and a less favorable non-operating position compared to the prior year when ordinary income reached 40.8B yen, suggesting prior-period gains from equity method investments or other non-operating items that did not recur.
The severe compression from ordinary income (22.0B yen) to net income (9.8B yen) was driven by an abnormally high effective tax rate of 59.0%. Income tax expense of 14.0B yen on pre-tax profit of 23.8B yen indicates probable tax adjustments related to M&A transactions, non-deductible goodwill amortization, or other structural tax factors. This represents a non-recurring or semi-recurring headwind requiring management attention for sustainable profit generation. This case exemplifies a "revenue up/profit down" pattern where top-line strength is overwhelmed by cost structure challenges and tax burdens, resulting in significant earnings quality deterioration despite operational expansion.
Recruitment Platform business generated revenue of 263.2B yen and operating income of 90.8B yen with a segment margin of 34.5%, establishing itself as the core profit engine contributing the vast majority of consolidated operating profit. This segment's high profitability reflects the scalability of the fee-based job matching platform model with limited incremental costs per transaction. Medical Platform business recorded revenue of 93.8B yen but operating loss of 4.5B yen (margin -4.8%), indicating ongoing investment phase with revenue scale not yet sufficient to cover fixed costs including system development, sales infrastructure, and the substantial goodwill amortization burden from acquisitions in this segment (7.8B yen goodwill balance at period-end, up from 3.2B yen prior year). The Medical Platform's negative profitability despite 27.3% revenue growth highlights the front-loaded investment nature of healthcare IT platform businesses. New Development Services showed revenue of 10.9B yen with operating loss of 7.7B yen (margin -70.7%), representing early-stage ventures where losses are expected during market entry and customer acquisition phases. The segment's 963M yen goodwill balance at period-end indicates acquisition-based entry strategy. Segment profitability dispersion is substantial, with the Recruitment Platform's 34.5% margin subsidizing losses in development-stage businesses. Unallocated corporate expenses of 5.7B yen bridge segment operating profit of 78.6B yen to consolidated operating income of 21.5B yen, representing headquarters overhead including management, finance, and shared service functions. The analysis confirms a portfolio structure where a mature, highly profitable recruitment business funds investment in medical and new platform development, creating near-term margin pressure but positioning for diversified long-term growth.
[Profitability] ROE of 6.6% reflects compressed profitability with net margin of 2.7% (net income 9.8B yen on revenue 367.9B yen), representing substantial deterioration from prior ROE levels driven by both the net income decline and equity base reduction. Operating margin of 5.8% decreased 2.1pt from 7.9% YoY, confirming margin compression from SG&A deleverage. The declining margins indicate that revenue growth is not translating into profit expansion, warranting operational efficiency improvements. [Cash Quality] Cash and deposits of 85.8B yen decreased markedly from 190.0B yen (-54.9%), creating heightened attention to liquidity management. Short-term debt coverage stands at 0.74x (cash versus current liabilities of 115.2B yen), down from prior comfortable levels, though current ratio of 128.7% and quick ratio of 124.7% indicate adequate near-term solvency. The cash decline resulted from strategic investments (M&A) and capital allocation decisions (share buybacks) rather than operational cash drain, as evidenced by strong operating cash flow generation. [Investment Efficiency] Total asset turnover of 0.89x (revenue 367.9B yen / average assets approximately 412.5B yen) reflects an asset-heavy balance sheet structure due to goodwill and intangible assets comprising 63.6% of total assets (232.5B yen intangibles + 128.6B yen goodwill = 361.1B yen / 567.5B yen total assets). This high intangible ratio is characteristic of platform businesses built through acquisitions but creates impairment sensitivity. [Financial Health] Equity ratio of 35.9% (148.0B yen equity / 412.5B yen assets) decreased from 44.7% in the prior period, reflecting equity reduction from share buybacks and accumulated losses. Debt-to-equity ratio of 0.83x (123.0B yen interest-bearing debt / 148.0B yen equity) remains within acceptable bounds. Current ratio of 128.7% and debt coverage by operating cash flow of 3.5 years (debt 123.0B yen / operating CF 34.9B yen) indicate manageable leverage, though the deteriorated equity base and cash position reduce financial flexibility for future investments or downturns.
Operating cash flow of 34.9B yen increased 42.5% YoY, representing 3.58x net income of 9.8B yen and confirming high-quality cash-backed earnings despite accounting profit decline. The operating CF exceeded net income due to substantial non-cash charges including depreciation and amortization of 11.0B yen, goodwill amortization of 13.6B yen (total non-cash deductions approximately 24.6B yen), and working capital efficiency with operating CF subtotal before working capital changes reaching 46.5B yen. Income taxes paid of 18.0B yen represented a significant cash outflow, while working capital movements showed inventory increase of 3.1B yen (building stock for business expansion) and minimal changes in receivables (+0.9B yen) and payables (-0.3B yen), indicating stable operational cash conversion. Investing cash flow of -71.3B yen was dominated by subsidiary share acquisitions of 66.2B yen for ASFON TRUST NETWORK and Axis Route Holdings consolidations, with minimal maintenance CapEx of 2.0B yen reflecting the asset-light platform business model. The investment intensity demonstrates aggressive M&A-driven growth strategy, resulting in goodwill and intangible asset accumulation. Financing cash flow of -67.8B yen reflected substantial share buybacks of 53.3B yen and net debt repayment, indicating capital allocation prioritizing shareholder returns and balance sheet management over cash retention. Free cash flow of -36.4B yen (operating CF 34.9B yen + investing CF -71.3B yen) turned negative due to M&A investments, though the underlying business generates strong positive operating cash flow. The cash position decrease from 190.0B yen to 85.8B yen (-104.2B yen change) reconciles to the combined impact of negative free cash flow and financing outflows, leaving reduced liquidity cushion for future flexibility. While operating fundamentals remain cash-generative, the financial strategy of concurrent M&A investment and large-scale buybacks has materially constrained available liquidity, creating monitoring requirements for debt covenants and future capital needs.
Ordinary income of 22.0B yen versus operating income of 21.5B yen shows minimal non-operating net contribution of approximately 0.5B yen, indicating that core business operations drive substantially all earnings with limited dependency on financial or investment income. Non-operating income of 4.6B yen primarily comprised interest and dividend income of 0.2B yen, equity method investment gains, and other gains of 0.6B yen, offset by non-operating expenses of 4.1B yen including interest expense of 1.7B yen on long-term debt and other expenses of 0.7B yen. Non-operating income represents 1.3% of revenue, a negligible proportion confirming earnings are predominantly operating-driven. Extraordinary items totaled net 1.7B yen gain (extraordinary income 2.0B yen less extraordinary loss 0.3B yen), constituting non-recurring factors that should be excluded from run-rate earnings assessments. The substantial divergence between ordinary income (22.0B yen) and net income (9.8B yen) is entirely attributable to the 14.0B yen income tax expense, representing an effective tax rate of 59.0% on pre-tax profit of 23.8B yen. This abnormally high tax rate likely reflects non-deductible goodwill amortization, M&A-related tax adjustments, or deferred tax liability recognition, creating a significant non-cash or semi-permanent earnings drag. Operating cash flow of 34.9B yen substantially exceeds net income of 9.8B yen by 3.58x, indicating excellent earnings quality from a cash realization perspective despite accounting profit compression. The operating CF/net income divergence is explained by large non-cash charges (depreciation 11.0B yen + goodwill amortization 13.6B yen = 24.6B yen) that reduce accounting earnings but not cash generation. Accrual-based adjustments are appropriate and the high operating cash conversion confirms that reported earnings understate true economic cash generation capability, though the elevated tax burden requires structural resolution for sustainable profit delivery.
Progress rate against full-year guidance shows revenue achievement of 79.3% (367.9B yen actual / 464.0B yen forecast) and operating income achievement of 72.9% (21.5B yen / 29.5B yen), indicating the company is slightly behind the standard 100% pro-rata pace for a full-year period but within reasonable range given typical quarterly seasonality patterns in recruitment and healthcare platform businesses. The revenue progress suggests moderate acceleration is needed in the final reporting phase to meet the 464.0B yen target, representing an additional 96.1B yen in incremental revenue. Operating income guidance of 29.5B yen (+37.2% YoY) implies 8.0B yen of operating profit to be generated in remaining periods, requiring significant margin improvement from the current 5.8% to approximately 8.3% on incremental revenue to achieve guidance. This recovery trajectory assumes SG&A cost rationalization, operating leverage emergence as revenue scales, and integration synergies from completed M&A transactions. Ordinary income guidance of 32.5B yen (+47.6% YoY) and implied EPS forecast of 58.25 yen suggest expected improvement in non-operating performance and moderation of the effective tax rate from the abnormal 59.0% level recorded in the current period toward a more normalized rate of approximately 39% (assuming net income aligns with EPS forecast of 18.0B yen on ordinary income of 32.5B yen, implying tax of 14.5B yen or 44% rate, still elevated). The guidance implies management confidence in second-half operational improvements and tax normalization, though execution risks remain given the significant step-up required in profitability from current run rates. The forecast assumptions likely incorporate full-year contribution from recent acquisitions, cost efficiency initiatives, and revenue seasonality favoring later periods, as referenced in qualitative disclosures noting that actual results may vary materially based on numerous factors.
Annual dividend remains at 0.00 yen for both interim and year-end, maintaining zero payout policy unchanged from prior periods. Payout ratio is 0% as no dividends were distributed against net income of 9.8B yen (30.62 yen per share). Despite the zero dividend policy, the company executed substantial share buybacks totaling 53.3B yen during the fiscal year, representing an aggressive capital return strategy prioritizing buybacks over dividends. Total return ratio reaches 545% when calculating (dividends 0B yen + buybacks 53.3B yen) / net income 9.8B yen, indicating shareholder returns far exceeding reported profits. This extraordinarily high total return ratio reflects management's commitment to capital efficiency and shareholder value even amid profit decline, though it raises questions regarding capital allocation priorities given concurrent cash-intensive M&A activity and the resulting liquidity reduction. The buyback activity reduced shares outstanding to 32,739K (treasury shares 1,839K), with average shares of 31,866K used for EPS calculation. The EPS forecast of 58.25 yen implies expected net income of approximately 18.0B yen (58.25 yen × 31,866K shares / 1,000), nearly doubling current period earnings. The dividend forecast remains 0.00 yen for the coming period, indicating continuation of zero payout policy. The combination of no dividends and large buybacks suggests a shareholder return philosophy prioritizing balance sheet optimization and EPS accretion over income distribution, appropriate for a growth-stage platform company but creating zero current income yield for income-oriented investors.
M&A integration risk represents the primary operational concern, with goodwill increasing 63.3% to 128.6B yen (86.9% of total equity of 148.0B yen) and intangible assets reaching 232.5B yen (56.4% of total assets), creating substantial impairment exposure if acquired businesses fail to deliver projected synergies or if market conditions deteriorate. The high concentration of intangible assets (goodwill plus intangible assets = 361.1B yen, representing 87.5% of total assets) means that even modest impairment charges of 10-15% would eliminate multiple years of earnings and materially damage equity.
Liquidity and financial flexibility constraints have emerged from the dual deployment of capital into M&A investments (66.2B yen in acquisitions) and share buybacks (53.3B yen), reducing cash from 190.0B yen to 85.8B yen (-54.9%) while maintaining debt of 123.0B yen. The debt-to-EBITDA ratio stands at 3.78x (debt 123.0B yen / EBITDA approximately 32.5B yen), approaching levels that could limit covenant flexibility. While current ratio of 128.7% and interest coverage of 12.4x remain adequate, the compressed cash position reduces buffers for adverse scenarios or opportunistic investments, with free cash flow negative at -36.4B yen indicating ongoing cash consumption when including strategic investments.
Tax burden sustainability and earnings quality risks are evidenced by the 59.0% effective tax rate (14.0B yen tax expense on 23.8B yen pre-tax income), far exceeding statutory rates and reflecting structural factors such as non-deductible goodwill amortization of 13.6B yen and potential deferred tax impacts. If this elevated tax rate persists rather than normalizing toward 30-35%, sustainable net margins will remain compressed below 3%, limiting ROE recovery and making the company less competitive relative to peers with normal tax structures. The tax issue creates earnings volatility and uncertainty around true economic profitability, requiring urgent management attention and disclosure.
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the healthcare platform and recruitment services sectors, where profitability benchmarks typically show ROE in the range of 10-15% for mature platform businesses and operating margins of 15-25% for scaled digital marketplaces. Against these industry characteristics, the company's ROE of 6.6% positions below median levels, reflecting both the profit compression from elevated costs and tax burdens, as well as the investment-stage nature of Medical Platform and New Development Services segments which are not yet contributing positive returns. The equity ratio of 35.9% compares to industry medians typically in the 40-50% range for asset-light platform businesses, indicating increased financial leverage from debt-funded growth and share buybacks reducing the equity base. Operating margin of 5.8% significantly trails industry benchmarks of 15-25% for scaled platforms, confirming that the company's current cost structure and investment spending create margin dilution relative to more mature peers or pure-play recruitment platforms without concurrent healthcare IT buildout. The Recruitment Platform segment's 34.5% operating margin aligns well with high-end industry profitability for established job platforms, suggesting that segment is competitive, while consolidated margin drag comes from development-stage segments and corporate overhead. The company's growth rate of 25.5% revenue increase substantially exceeds typical industry growth of 5-10% for mature players, positioning the company in a high-growth/lower-profitability quadrant relative to peers, consistent with an aggressive expansion and M&A strategy. Industry positioning summary: above-average growth with below-average profitability and financial strength metrics, indicating strategic prioritization of scale and market share over near-term margins, with success dependent on achieving operating leverage as platforms mature.
Profitability: ROE 6.6% (Industry Median 12-15%)
Financial Health: Equity Ratio 35.9% (Industry Median 40-50%)
Efficiency: Operating Margin 5.8% (Industry Median 15-25%)
※ Industry: Healthcare Platform / Recruitment Services (reference peer group), Comparison: Current period company metrics versus typical industry ranges, Source: Proprietary analysis
Revenue growth momentum remains robust at 25.5% driven by both organic platform expansion and M&A contributions, with full-year guidance of 464.0B yen (+26.1%) indicating confidence in sustained top-line trajectory. The Recruitment Platform segment demonstrates strong unit economics with 34.5% operating margin and serves as the primary cash generator funding investment in Medical Platform and new ventures. Operating cash flow strength of 34.9B yen (+42.5% YoY) and operating CF to net income ratio of 3.58x confirm high-quality underlying cash generation despite accounting profit decline, indicating the business model successfully converts revenue into cash even amid investment spending.
Profitability and margin structure require urgent attention, with operating margin compressed to 5.8% (-2.1pt YoY) due to SG&A growing faster than revenue and elevated goodwill amortization of 13.6B yen. The 59.0% effective tax rate creates a structural earnings headwind that must be addressed through tax planning or business restructuring to achieve sustainable net profitability. The combination of negative operating leverage and abnormal tax burden has driven ROE to 6.6%, below acceptable return thresholds, requiring management action on cost efficiency and tax optimization to restore shareholder value creation. Guidance implies second-half margin recovery to approximately 8-10% operating margin on incremental revenue, though execution risk is notable given current run-rate performance.
Capital allocation and balance sheet sustainability present mixed signals, with aggressive M&A investment (66.2B yen) and massive share buybacks (53.3B yen) demonstrating commitment to growth and shareholder returns but reducing cash from 190.0B yen to 85.8B yen (-54.9%) and compressing equity ratio to 35.9%. The resulting intangible asset concentration (87.5% of assets in goodwill and intangibles) creates elevated impairment risk, while debt-to-EBITDA of 3.78x and reduced liquidity constrain financial flexibility. The capital structure remains serviceable with interest coverage of 12.4x, but the company has materially reduced its margin of safety for adverse scenarios or additional investments. Future capital allocation must balance growth ambitions with balance sheet preservation, potentially moderating buyback intensity or requiring equity raises if M&A pipeline continues.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.